Trials / Sponsors / Miltenyi Biomedicine GmbH
Miltenyi Biomedicine GmbH
Industry · 18 registered clinical trials — 11 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | M-2018-334 in Hematological Malignancies Hematological Malignancies | N/A | 2026-02-28 |
| Not Yet Recruiting | MB-CART2019.1 in Refractory Multiple Sclerosis Multiple Sclerosis, CAR T Cell Therapy | Phase 1 / Phase 2 | 2026-01-30 |
| Recruiting | DALY II Japan/MB-CART2019.1 for DLBCL DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy | Phase 2 | 2025-12-11 |
| Recruiting | Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell N B-Cell Neoplasm | Phase 2 | 2025-08-04 |
| Not Yet Recruiting | US Zamto-cel Autoimmune Diseases Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | Phase 1 | 2025-01-01 |
| Recruiting | MB-CART19.1 in Refractory SLE SLE - Systemic Lupus Erythematosus | Phase 1 / Phase 2 | 2024-08-12 |
| Recruiting | MB-dNPM1-TCR.1 in Relapsed/Refractory AML Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | 2024-08-01 |
| Recruiting | Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU Non Hodgkin Lymphoma | — | 2024-05-15 |
| Recruiting | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL | N/A | 2024-05-05 |
| Recruiting | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis | Phase 1 / Phase 2 | 2023-07-17 |
| Active Not Recruiting | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients Diffuse Large B-cell Lymphoma | Phase 2 | 2021-08-18 |
| Recruiting | DALY II USA/ MB-CART2019.1 for DLBCL Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL) | Phase 2 | 2021-05-25 |
| Completed | A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers COVID-19 | — | 2020-04-22 |
| Terminated | MB-CART20.1 Melanoma Melanoma (Skin) | EARLY_Phase 1 | 2019-03-08 |
| Completed | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) B-cell Non Hodgkin Lymphoma | Phase 1 | 2019-02-25 |
| Active Not Recruiting | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 | 2018-11-26 |
| Completed | MB-CART20.1 Lymphoma Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | 2018-09-25 |
| Completed | Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis Preeclampsia | N/A | 2016-09-01 |